Fairvalue-Calculator Fairvalue-Calculator
EN DE

Restart Life Sciences Corp (NMLSF) Fair Value & Analysis

Healthcare · US · Market cap $4.4M

Price$0.0491
Fair Value$0.0348
Upside-29.1%
Quality95/100
Evidence: Low Range $0.0348 – $0.0397

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Restart Life Sciences Corp (NMLSF) currently trades at $0.0491, while our model-based Fair Value estimate is $0.0348 — implying the stock looks roughly 29.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Restart Life Sciences Corp (NMLSF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0348 versus a price of $0.0491 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NMLSF?
Our 21-model fair value for Restart Life Sciences Corp is $0.0348 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0491.
What is the quality score of NMLSF?
Restart Life Sciences Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.